Rhythm Pharmaceuticals announced positive Phase 3 TRANSCEND trial data for setmelanotide in acquired hypothalamic obesity, showing an 18.8% placebo-adjusted BMI reduction difference across 142 patients at 52 weeks. The company's supplemental New Drug Application (sNDA) is under FDA review with a PDUFA goal date of March 20, 2026, and the company also plans regulatory submissions in Europe and Japan.

Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.

Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results.

Rhythm Pharmaceuticals reported strong Q1 2025 results, with $37.7 million in net product revenue from IMCIVREE and positive data from its pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The company also provided updates on its pipeline and anticipated upcoming milestones.

Rhythm Pharmaceuticals announced positive topline results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity. The trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide compared to placebo in both adult and pediatric patients.

Rhythm Pharmaceuticals and the Raymond A. Wood Foundation have announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma, a rare neuroendocrine disease. The goal is to better understand the experiences of craniopharyngioma survivors and factors that may affect fatigue, such as weight gain and daytime sleepiness.

The obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

Rhythm Pharmaceuticals and Axovia Therapeutics have announced a joint research collaboration to advance the understanding of Bardet-Biedl syndrome, a rare genetic disorder. The collaboration aims to improve the lives of patients and their families living with this disease.

Rhythm Pharmaceuticals, a biopharmaceutical company, announced the grant of inducement restricted stock units to nine new employees. The RSUs are subject to the company's 2022 Employment Inducement Plan and vest over four years.

Rhythm Pharmaceuticals, a biopharmaceutical company, announced the grant of inducement restricted stock units to four new employees. The RSUs are subject to the company's 2022 Employment Inducement Plan and vest over four years.

- European Commission decision anticipated in the second half of 2024 -

Rhythm Pharmaceuticals' financial health appears stable, with a sufficient cash runway extended by recent funding. See why RYTM stock is a Hold.